Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer

Abstract

Pre-treatment lymphocytopaenia is an independent adverse prognostic factor in both muscle-invasive and advanced bladder cancer. It may be a manifestation of cancer-induced immune suppression driving tumour progression.

Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation

“…Furthermore, it is noteworthy that lymphopenia has been identified as a prognostic factor in HCC. To date, in other solid tumors including breast, renal, colorectal, prostate, and bladder cancer, lymphopenia has been proposed as a poor prognostic factor . As lymphocytes are a crucial part of antitumor immunity, lymphopenia can be a surrogate marker of tumor‐induced immune suppression.…”

“…To date, in other solid tumors including breast, renal, colorectal, prostate, and bladder cancer, lymphopenia has been proposed as a poor prognostic factor. 28 As lymphocytes are a crucial part of antitumor immunity, lymphopenia can be a surrogate marker of tumor-induced immune suppression. To our knowledge, this is the first study to address the role of lymphopenia in HCC patients treated with RFA.…”

Prognostic value of inflammation-based scores in patients with osteosarcoma

“…Neutrophilia, thrombocytosis, monocytosis and lymphopenia tend to represent a nonspecific response to cancer-related inflammation and are associated with poor survival in cancers3233343536. Neutrophils interact with tumor cells by producing cytokines and chemokines, which affects tumor cells’ proliferation, angiogenesis, and metastases37.…”

Role of systemic inflammatory response markers in urological malignancy

“…The SIR can be monitored using two categories of indices: concentration of specific serum proteins (albumin, CRP, fibrinogen) and a differential blood cell count (neutrophil, lymphocyte, monocyte, platelet) . Many researchers have investigated the prognostic value of these SIR markers in various types of cancer . Furthermore, combinations of these indices, such as the GPS, which consists of the serum CRP and albumin level; the NLR; the PLR; and the PNI, which is based on peripheral blood lymphocyte count and serum albumin level, have also been evaluated and compared in cancer research, including urological cancers .…”

“…13 Many researchers have investigated the prognostic value of these SIR markers in various types of cancer. [14][15][16][17] Furthermore, combinations of these indices, such as the GPS, which consists of the serum CRP and albumin level; the NLR; the PLR; and the PNI, which is based on peripheral blood lymphocyte count and serum albumin level, have also been evaluated and compared in cancer research, including urological cancers. [18][19][20][21][22][23] Most studies have evaluated the prognostic and predictive role of pretreatment SIR markers, although some have focused on the role of post-treatment SIR markers at specific points during the clinical course.…”